The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jun. 08, 2021
Filed:
Dec. 30, 2019
Applicant:
Aerie Pharmaceuticals, Inc., Bedminster, NJ (US);
Inventors:
Mitchell A. deLong, Chapel Hill, NC (US);
Jill Marie Sturdivant, Chapel Hill, NC (US);
Susan M. Royalty, Davis, CA (US);
Assignee:
Aerie Pharmaceuticals, Inc., Bedminster, NJ (US);
Primary Examiner:
Int. Cl.
CPC ...
C07D 417/12 (2006.01); C07C 237/20 (2006.01); C07D 401/12 (2006.01); C07D 409/12 (2006.01); C07D 217/00 (2006.01); C07C 237/42 (2006.01); C07D 333/40 (2006.01); C07D 217/04 (2006.01); C07D 217/02 (2006.01); C07D 217/22 (2006.01); C07D 217/24 (2006.01); C07D 405/12 (2006.01); C07D 413/12 (2006.01); C07D 333/38 (2006.01);
U.S. Cl.
CPC ...
C07D 417/12 (2013.01); C07C 237/20 (2013.01); C07C 237/42 (2013.01); C07D 217/00 (2013.01); C07D 217/02 (2013.01); C07D 217/04 (2013.01); C07D 217/22 (2013.01); C07D 217/24 (2013.01); C07D 333/38 (2013.01); C07D 333/40 (2013.01); C07D 401/12 (2013.01); C07D 405/12 (2013.01); C07D 409/12 (2013.01); C07D 413/12 (2013.01); C07C 2601/08 (2017.05); C07C 2601/14 (2017.05);
Abstract
Provided are compounds that are inhibitors of both rho kinase and of a monoamine transporter (MAT) act to improve the disease state or condition. Further provided are compositions comprising the compounds. Further provided are methods for treating diseases or conditions, the methods comprising administering compounds according to the invention. One such disease may be glaucoma for which, among other beneficial effects, a marked reduction in intraocular pressure (IOP) may be achieved.